American Diabetes Association Highlights New Developments in Diabetes Technology
June 26th 2023The American Diabetes Association showcased advancements in diabetes technology revolving around improving glucose control devices and treating diabetic retinopathy at the 83rd Scientific Sessions.
Read More
Patients with ST-segment elevation myocardial infarction who are uninsured were not found to be transferred between facilities at a higher rate than insured patients, and the amount of transfers were instead based more on the capability of a facility to provide percutaneous coronary intervention in a timely fashion.
Read More
New Model Risk Factors for HIV in Women Include Pregnancy, Hepatitis C, and Substance Use
June 23rd 2023Model produces information that can lead to individual providers identifying women who may need more targeted and more frequent HIV testing or be good candidates for preexposure prophylaxis.
Read More
Liso-Cel Produces Deep, Durable Responses in Patients with Hard-to-Treat Lymphomas
June 22nd 2023Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.
Read More
Common Antibiotics Associated with C. difficile Infection Include Piperacillin, Meropenem
June 21st 2023Antibiotics that were found to be most commonly associated with clostridium difficile infection are piperacillin/tazobactam, meropenem, vancomycin, ciprofloxacin, ceftriaxone, and levofloxacin, according to a recent study.
Read More
Current Dementia Risk Assessment Models Limited in Ability to Predict Disease
June 20th 2023Standard prediction models that assess an individual’s risk of developing dementia and how to prevent it are limited in their ability to do so, showing high error rates and a higher chance of receiving a false-positive result, according to a recent study.
Read More
Axi-Cel Use in Patients With Large B-Cell Lymphoma Leads to Longer Overall Survival
June 16th 2023A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.
Read More
Cilta-Cel Shows Long-Term Efficacy in Patients With Relapsed/Refractory Multiple Myeloma
June 13th 2023A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More